Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.54 |
| ▸ | HPGD | P15428 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975797 | 0.78 | ALDH1A1 (0.52) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14263114 | 0.76 | DRD4 (0.73) | HPGDSMN1; SMN2GAAMAPT | |
| SCHEMBL22581417 | 0.74 | KDM4E (0.76) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL4982505 | 0.72 | DRD4 (0.51) | HPGDALDH1A1MAPT | |
| SCHEMBL25878621 | 0.72 | RAB9A (0.57) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL8129921 | 0.72 | TSHR (0.56) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL4982989 | 0.72 | NPC1 (0.57) | ALDH1A1TP53GAA | |
| SCHEMBL4981056 | 0.72 | ALDH1A1 (0.55) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL14391516 | 0.71 | HPGD (0.50) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL357853 | 0.71 | HPGD (0.50) | HPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | KDM4E 1044/4885HPGD 1184/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.